New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

3 September 2020

Updated results published today in the prestigious New England Journal of Medicine herald the long-term effectiveness of a targeted combination drug therapy given after surgery in patients with high risk early melanoma.

The international study reports that in patients with Stage III BRAF-positive melanoma who were treated with adjuvant targeted therapy, there can be a long-lasting benefit from the treatment in preventing the disease from recurring.

In the Phase III trial, known as COMBI-AD, patients were treated with either a combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) or placebo given after surgery. The trial demonstrated early promising results after 12 months of treatment and significantly improved recurrence-free survival.

This latest publication revealed the effects of treatment have continued to be sustained after five years. In patients who received the combination therapy, 52% had no disease recurrence after five years. By comparison, only 36% of those patients on placebo – which was the standard of care at the time - had no disease recurrence during this time.

“Our research has demonstrated that many patients have long-term benefit on adjuvant combination targeted therapy, and it may be curative in most of those patients,” says co-senior author and Co-Medical Director of Melanoma Institute Australia Professor Georgina Long AO.

The study shows that adjvuant targeted therapy for patients with the BRAF mutation prevents recurrence in high-risk stage III melanoma.

“Melanoma Institute Australia is working closely with our international collaborators to take major steps forward in cancer treatment,” says Professor Long. “These results take us even closer to reaching our goal of zero deaths from melanoma this decade.”

 

Journal publication:

Reinhard Dummer, M.D., Axel Hauschild, M.D.,Mario Santinami, M.D., Victoria Atkinson, M.D., Mario Mandalà, M.D., John M. Kirkwood, M.D., Vanna Chiarion Sileni, M.D., James Larkin, M.D., Ph.D., Marta Nyakas, M.D., Caroline Dutriaux, M.D., Andrew Haydon, M.B., B.S., Ph.D., Caroline Robert, M.D., Ph.D., Laurent Mortier, M.D., Ph.D., Jacob Schachter, .D., Thierry Lesimple, M.D., Ruth Plummer, M.D., Kohinoor Dasgupta, Ph.D., Eduard Gasal, M.D., Monique Tan, M.D., Georgina V. Long, M.B., B.S., Ph.D., and Dirk Schadendorf, M.D.

(2020) Five-Year Relapse-Free Survival With Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutant Melanoma. NEJM. 

Read online here

Melanoma Patients Australia Symposium - Webinar 2
30 Sep 2020

Melanoma Patients Australia Symposium - Webinar 2

Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.

City2Surf 2020
18 Oct 2020

City2Surf 2020

You're invited to be a C2S charity superstar, and together we can run over melanoma!

City2Surf 2020
11 Sep 2020

City2Surf 2020

Join in the fun of the virtual event, and together we can run over melanoma!

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts from MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Melanoma Supportive Care Needs research study. 
03 Sep 2020

Melanoma Supportive Care Needs research study. 

Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New online melanoma risk calculators critical to saving lives
28 Aug 2020

New online melanoma risk calculators critical to saving lives

Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Tags: melanoma
Professor Richard Scolyer receives University of Sydney Alumni Award.
24 Aug 2020

Professor Richard Scolyer receives University of Sydney Alumni Award.

MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Tags: melanoma
Uniting together despite the distance
21 Aug 2020

Uniting together despite the distance

More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Tags: melanoma
Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
03 Aug 2020

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.

For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Tags: melanoma
Important Update: Masks required at Poche Centre
24 Jul 2020

Important Update: Masks required at Poche Centre

As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask. 

Tags: melanoma
A Critical Nexus:The Clinician and the Researcher.
14 Jul 2020

A Critical Nexus:The Clinician and the Researcher.

In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.    

Tags: melanoma
New online calculator launched to determine risk of spread of melanoma
15 Jun 2020

New online calculator launched to determine risk of spread of melanoma

Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.

Tags: melanoma
Queen's Birthday Honour for Professor Georgina Long
08 Jun 2020

Queen's Birthday Honour for Professor Georgina Long

Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for  distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies. 

Tags: melanoma
Danny's inspiring survival story
30 May 2020

Danny's inspiring survival story

“I had a complete response within about six months. All of my tumours disappeared."

Tags: melanoma
MIA in the spotlight at ASCO virtual conference
30 May 2020

MIA in the spotlight at ASCO virtual conference

‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'

Tags: melanoma
Professor Richard Scolyer achieves h-index of 100
26 May 2020

Professor Richard Scolyer achieves h-index of 100

MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.

How we connected at Melanoma March Virtual 2020
21 Apr 2020

See how we connected at Melanoma March Virtual 2020

We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.

Melanoma meets its match.
07 Apr 2020

Melanoma meets its match.

A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.  

 

Next Steps for National Screening Program for Melanoma
23 Mar 2020

Next Steps for National Screening Program for Melanoma

On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.